FDA Announces Efforts to Implement Real-Time Clinical Trial Reporting.
- In the news
FDA initiates real-time reporting pilot with two proof-of-concept clinical trials, including AstraZeneca’s TrAVeRse and Amgen’s STREAM-SCLC studies.
- Why it matters: Real-time clinical trial data reporting can improve transparency, accelerate data sharing, and enhance decision-making in drug development, addressing current delays in information dissemination.
- What they did: The FDA launched a pilot program involving two clinical trials—one phase II and one phase Ib—focused on mantle cell lymphoma and small cell lung carcinoma, respectively, to test real-time endpoint and data signal reporting.
- The result: This initiative could lead to more dynamic and efficient clinical trial processes, enabling faster responses to emerging data and potentially improving patient outcomes and regulatory oversight.